Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review

Nivolumab (PD-1 inhibitor) and other immune checkpoint inhibitors are used primarily to promote reactivation of anti-tumor immunity. However, due to their generalized immunorestorative properties, these agents may also trigger an unusual spectrum of side-effects termed immune-related adverse events....

Descripción completa

Detalles Bibliográficos
Autores principales: van Eeden, Ronwyn, Rapoport, Bernardo L., Smit, Teresa, Anderson, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668214/
https://www.ncbi.nlm.nih.gov/pubmed/31396484
http://dx.doi.org/10.3389/fonc.2019.00659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668214/
https://www.ncbi.nlm.nih.gov/pubmed/31396484
http://dx.doi.org/10.3389/fonc.2019.00659

Ejemplares similares